{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:17:39Z","timestamp":1767961059326,"version":"3.49.0"},"reference-count":204,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The use of cancer biomarkers to anticipate the outlines of disease has been an emerging issue, especially as cancer treatment has made such positive steps in the last few years. Progress in the development of consistent malignancy markers is imminent because advances in genomics and bioinformatics have allowed the examination of immense amounts of data. Osteopontin is a phosphorylated glycoprotein secreted by activated macrophages, leukocytes, and activated T lymphocytes, and is present in extracellular fluids, at sites of inflammation, and in the extracellular matrix of mineralized tissues. Several physiologic roles have been attributed to osteopontin, i.e., in inflammation and immune function, in mineralized tissues, in vascular tissue, and in kidney. Osteopontin interacts with a variety of cell surface receptors, including several integrins and CD44. Binding of osteopontin to these cell surface receptors stimulates cell adhesion, migration, and specific signaling functions. Overexpression of osteopontin has been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, stomach cancer, ovarian cancer, and melanoma. Moreover, osteopontin is present in elevated levels in the blood and plasma of some patients with metastatic cancers. Therefore, suppression of the action of osteopontin may confer significant therapeutic activity, and several strategies for bringing about this suppression have been identified. This review looks at the recent advances in understanding the possible mechanisms by which osteopontin may contribute functionally to malignancy, particularly in breast cancer. Furthermore, the measurement of osteopontin in the blood or tumors of patients with cancer, as a way of providing valuable prognostic information, will be discussed based on emerging clinical data. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1087\u201397)<\/jats:p>","DOI":"10.1158\/1055-9965.epi-06-1008","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T19:27:49Z","timestamp":1180985269000},"page":"1087-1097","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer"],"prefix":"10.1158","volume":"16","author":[{"given":"Li\u0301gia R.","family":"Rodrigues","sequence":"first","affiliation":[{"name":"1Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Campus de Gualtar, Braga, Portugal;"}]},{"given":"Jose\u0301 A.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"1Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Campus de Gualtar, Braga, Portugal;"}]},{"given":"Fernando L.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"2Instituto de Patologia e Imunologia Molecular,"},{"name":"3Faculdade de Medicina, Universidade do Porto, Oporto, Portugal;"}]},{"given":"Marie","family":"Paulsson","sequence":"additional","affiliation":[{"name":"4Department of Food Technology, Engineering, and Nutrition, Lund University; and"}]},{"given":"Helena","family":"Lindmark-Ma\u0308nsson","sequence":"additional","affiliation":[{"name":"4Department of Food Technology, Engineering, and Nutrition, Lund University; and"},{"name":"5Swedish Dairy Association, Lund, Sweden"}]}],"member":"1086","published-online":{"date-parts":[[2007,6,4]]},"reference":[{"key":"2022061002321380800_BIB1","unstructured":"Kelloff GJ, Boone CW, Crowell JA, et al. Risk biomarkers and current strategies for cancer chemoprevention. Clin Chem\u20081996;48:1160\u20139."},{"key":"2022061002321380800_BIB2","doi-asserted-by":"crossref","unstructured":"Henson DE, Srivastava S, Kramer BS. Molecular and genetic targets in early detection. Curr Opin Oncol\u20081999;11:419\u201325.","DOI":"10.1097\/00001622-199909000-00018"},{"key":"2022061002321380800_BIB3","doi-asserted-by":"crossref","unstructured":"Baker SG. Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics\u20082000;56:1082\u20137.","DOI":"10.1111\/j.0006-341X.2000.01082.x"},{"key":"2022061002321380800_BIB4","doi-asserted-by":"crossref","unstructured":"Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst\u20082001;93:1054\u201361.","DOI":"10.1093\/jnci\/93.14.1054"},{"key":"2022061002321380800_BIB5","unstructured":"Sueoka E, Sueoka N, Goto Y, et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res\u20082001;61:1896\u2013902."},{"key":"2022061002321380800_BIB6","doi-asserted-by":"crossref","unstructured":"Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem\u20082002;48:1198\u2013205.","DOI":"10.1093\/clinchem\/48.8.1198"},{"key":"2022061002321380800_BIB7","unstructured":"Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas\/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res\u20082002;62:1868\u201375."},{"key":"2022061002321380800_BIB8","doi-asserted-by":"crossref","unstructured":"Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neurooncol\u20082002;58:217\u201336.","DOI":"10.1023\/A:1016218117251"},{"key":"2022061002321380800_BIB9","doi-asserted-by":"crossref","unstructured":"Ross JS, Fletcher JA, Linette GP, et al. The HER-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist\u20082003;8:307\u201325.","DOI":"10.1634\/theoncologist.8-4-307"},{"key":"2022061002321380800_BIB10","doi-asserted-by":"crossref","unstructured":"Ross JS, Linette GP, Stec JCE, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn\u20082003;3:573\u201385.","DOI":"10.1586\/14737159.3.5.573"},{"key":"2022061002321380800_BIB11","doi-asserted-by":"crossref","unstructured":"Ross JS, Linette GP, Stec JCE, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn\u20082004;4:169\u201388.","DOI":"10.1586\/14737159.4.2.169"},{"key":"2022061002321380800_BIB12","doi-asserted-by":"crossref","unstructured":"Verma M, Wright GI, Jr., Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci\u20082001;945:103\u201315.","DOI":"10.1111\/j.1749-6632.2001.tb03870.x"},{"key":"2022061002321380800_BIB13","unstructured":"Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res\u20082001;61:5974\u20138."},{"key":"2022061002321380800_BIB14","doi-asserted-by":"crossref","unstructured":"Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem\u20082002;48:1296\u2013304.","DOI":"10.1093\/clinchem\/48.8.1296"},{"key":"2022061002321380800_BIB15","unstructured":"Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem\u20082002;48:1160\u20139."},{"key":"2022061002321380800_BIB16","doi-asserted-by":"crossref","unstructured":"Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer\u20082003;3:267\u201375.","DOI":"10.1038\/nrc1043"},{"key":"2022061002321380800_BIB17","doi-asserted-by":"crossref","unstructured":"Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics\u20082004;3:367\u201378.","DOI":"10.1074\/mcp.R400007-MCP200"},{"key":"2022061002321380800_BIB18","unstructured":"Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer\/testis antigens as biomarkers in lung carcinoma. Cancer Res\u20082002;62:3971\u20139."},{"key":"2022061002321380800_BIB19","doi-asserted-by":"crossref","unstructured":"Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg\u20082001;233:630\u20138.","DOI":"10.1097\/00000658-200105000-00006"},{"key":"2022061002321380800_BIB20","doi-asserted-by":"crossref","unstructured":"Fenech M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today\u20082002;7:1128\u201337.","DOI":"10.1016\/S1359-6446(02)02502-3"},{"key":"2022061002321380800_BIB21","doi-asserted-by":"crossref","unstructured":"Pritzker KPH. Cancer biomarkers: easier said than done. Clin Chem\u20082002;48:1147\u201350.","DOI":"10.1093\/clinchem\/48.8.1147"},{"key":"2022061002321380800_BIB22","doi-asserted-by":"crossref","unstructured":"Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr\u20082002;132:2471\u20135.","DOI":"10.1093\/jn\/132.8.2471S"},{"key":"2022061002321380800_BIB23","doi-asserted-by":"crossref","unstructured":"Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med\u20082001;1:621\u201332.","DOI":"10.2174\/1566524013363339"},{"key":"2022061002321380800_BIB24","doi-asserted-by":"crossref","unstructured":"Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta\u20082001;552:61\u201385.","DOI":"10.1016\/S0304-419X(01)00037-3"},{"key":"2022061002321380800_BIB25","doi-asserted-by":"crossref","unstructured":"Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques\u20082001;30:670\u20135.","DOI":"10.2144\/01303dd05"},{"key":"2022061002321380800_BIB26","doi-asserted-by":"crossref","unstructured":"Kim J-H, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA\u20082002;287:1671\u20139.","DOI":"10.1001\/jama.287.13.1671"},{"key":"2022061002321380800_BIB27","doi-asserted-by":"crossref","unstructured":"Brown LF, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell\u20081992;3:1169\u201380.","DOI":"10.1091\/mbc.3.10.1169"},{"key":"2022061002321380800_BIB28","unstructured":"Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res\u20081988;48:5770\u20134."},{"key":"2022061002321380800_BIB29","unstructured":"Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res\u20081989;9:1291\u20139."},{"key":"2022061002321380800_BIB30","doi-asserted-by":"crossref","unstructured":"Shiraga H, Min W, Vandusen WJ, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci U S A\u20081992;89:426\u201330.","DOI":"10.1073\/pnas.89.1.426"},{"key":"2022061002321380800_BIB31","doi-asserted-by":"crossref","unstructured":"Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr\u20082000;27:17\u201337.","DOI":"10.1093\/oxfordjournals.jncimonographs.a024241"},{"key":"2022061002321380800_BIB32","unstructured":"Rittling SR, Novick KE. Osteopontin expression in mammary gland development and tumorgenesis. Cell Growth Differ\u20081997;8:1061\u20139."},{"key":"2022061002321380800_BIB33","doi-asserted-by":"crossref","unstructured":"Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res\u20081998;13:1101\u201311.","DOI":"10.1359\/jbmr.1998.13.7.1101"},{"key":"2022061002321380800_BIB34","doi-asserted-by":"crossref","unstructured":"Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem\u20082000;275:969\u201376.","DOI":"10.1074\/jbc.275.2.969"},{"key":"2022061002321380800_BIB35","doi-asserted-by":"crossref","unstructured":"Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin \u03b1v\u03b23. Cell\u20081996;85:683\u201393.","DOI":"10.1016\/S0092-8674(00)81235-0"},{"key":"2022061002321380800_BIB36","doi-asserted-by":"crossref","unstructured":"Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin \u03b1v\u03b23 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer\u20082000;86:15\u201323.","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B"},{"key":"2022061002321380800_BIB37","doi-asserted-by":"crossref","unstructured":"Butler WT. The nature and significance of osteopontin. Connect Tissue Res\u20081989;23:123\u201336.","DOI":"10.3109\/03008208909002412"},{"key":"2022061002321380800_BIB38","doi-asserted-by":"crossref","unstructured":"Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med\u20082000;11:279\u2013303.","DOI":"10.1177\/10454411000110030101"},{"key":"2022061002321380800_BIB39","doi-asserted-by":"crossref","unstructured":"Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A\u20081986;83:8819\u201323.","DOI":"10.1073\/pnas.83.23.8819"},{"key":"2022061002321380800_BIB40","doi-asserted-by":"crossref","unstructured":"McKee MD, Farach-Carson MC, Butler WT, Hauschka PV, Nanci A. Ultrastructural immunolocalization of noncollagenous (osteopontin and osteocalcin) and plasma (albumin and \u03b12HS-glycoprotein) proteins in rat bone. J Bone Miner Res\u20081993;8:485\u201396.","DOI":"10.1002\/jbmr.5650080413"},{"key":"2022061002321380800_BIB41","doi-asserted-by":"crossref","unstructured":"Goldberg HA, Hunter GK. The inhibitory activity of osteopontin on hydroxyapatite formation in vitro. Ann N Y Acad Sci\u20081995;760:305\u20138.","DOI":"10.1111\/j.1749-6632.1995.tb44642.x"},{"key":"2022061002321380800_BIB42","doi-asserted-by":"crossref","unstructured":"Nagata T, Bellows CG, Kasugai S, Butler WT, Sodek J. Biosynthesis of bone proteins (SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)) in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem J\u20081991;274:513\u201320.","DOI":"10.1042\/bj2740513"},{"key":"2022061002321380800_BIB43","doi-asserted-by":"crossref","unstructured":"Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J\u20081996;317:59\u201364.","DOI":"10.1042\/bj3170059"},{"key":"2022061002321380800_BIB44","doi-asserted-by":"crossref","unstructured":"Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin \u03b1v\u03b23 potentiate bone resorption. J Biol Chem\u20081993;268:9901\u20137.","DOI":"10.1016\/S0021-9258(18)98430-9"},{"key":"2022061002321380800_BIB45","doi-asserted-by":"crossref","unstructured":"Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol\u20082000;19:615\u201322.","DOI":"10.1016\/S0945-053X(00)00108-6"},{"key":"2022061002321380800_BIB46","doi-asserted-by":"crossref","unstructured":"McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res\u20081996;35:197\u2013205.","DOI":"10.3109\/03008209609029192"},{"key":"2022061002321380800_BIB47","doi-asserted-by":"crossref","unstructured":"Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med\u20081989;170:145\u201361.","DOI":"10.1084\/jem.170.1.145"},{"key":"2022061002321380800_BIB48","unstructured":"Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1\/osteopontin gene. Crit Rev Immunol\u20081993;13:225\u201346."},{"key":"2022061002321380800_BIB49","unstructured":"Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol\u20081998;152:353\u20138."},{"key":"2022061002321380800_BIB50","doi-asserted-by":"crossref","unstructured":"Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science\u20082000;287:860\u20134.","DOI":"10.1126\/science.287.5454.860"},{"key":"2022061002321380800_BIB51","doi-asserted-by":"crossref","unstructured":"Santana MA, Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol\u20082003;195:392\u2013401.","DOI":"10.1002\/jcp.10258"},{"key":"2022061002321380800_BIB52","doi-asserted-by":"crossref","unstructured":"Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest\u20081998;101:1468\u201378.","DOI":"10.1172\/JCI2131"},{"key":"2022061002321380800_BIB53","doi-asserted-by":"crossref","unstructured":"Prince CW, Oosawa T, Butler WT, et al. Isolation, characterization and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem\u20081987;262:2900\u20137.","DOI":"10.1016\/S0021-9258(18)61592-3"},{"key":"2022061002321380800_BIB54","doi-asserted-by":"crossref","unstructured":"Zhang Q, Domenicucci C, Goldberg HA, Wrana JL, Sodek J. Characterization of fetal porcine bone sialoproteins, secreted phosphoprotein I (SPPI, osteopontin), bone sialoprotein, and a 23-kDa glycoprotein. Demonstration that the 23-kDa glycoprotein is derived from the carboxyl terminus of SPPI. J Biol Chem\u20081990;265:7583\u20139.","DOI":"10.1016\/S0021-9258(19)39154-9"},{"key":"2022061002321380800_BIB55","doi-asserted-by":"crossref","unstructured":"Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem\u20081987;262:9702\u20138.","DOI":"10.1016\/S0021-9258(18)47991-4"},{"key":"2022061002321380800_BIB56","doi-asserted-by":"crossref","unstructured":"Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J\u20081985;232:715\u201324.","DOI":"10.1042\/bj2320715"},{"key":"2022061002321380800_BIB57","doi-asserted-by":"crossref","unstructured":"Fet V, Dickinson ME, Hogan BL. Localization of the mouse gene for secreted phosphoprotein 1 (Spp-1) (2ar osteopontin, bone sialoprotein 1, 44-kDa bone phosphoprotein, tumor-secreted phosphoprotein) to chromosome 5, closely linked to Ric (Rickettsia resistance). Genomics\u20081989;5:375\u20137.","DOI":"10.1016\/0888-7543(89)90074-8"},{"key":"2022061002321380800_BIB58","doi-asserted-by":"crossref","unstructured":"Craig AM, Denhardt DT. The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene\u20081991;100:163\u201371.","DOI":"10.1016\/0378-1119(91)90362-F"},{"key":"2022061002321380800_BIB59","doi-asserted-by":"crossref","unstructured":"Denhardt DT, Lopez CA, Rollo EE, et al. Osteoponyin-induced modifications of cellular functions. Ann N Y Acad Sci\u20081995;760:127\u201342.","DOI":"10.1111\/j.1749-6632.1995.tb44625.x"},{"key":"2022061002321380800_BIB60","doi-asserted-by":"crossref","unstructured":"Craig AM, Smith JH, Denhardt DT. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem\u20081989;264:9682\u20139.","DOI":"10.1016\/S0021-9258(18)60584-8"},{"key":"2022061002321380800_BIB61","doi-asserted-by":"crossref","unstructured":"Kiefer MC, Bauer DM, Barr PJ. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res\u20081989;17:3306.","DOI":"10.1093\/nar\/17.8.3306"},{"key":"2022061002321380800_BIB62","doi-asserted-by":"crossref","unstructured":"Wrana JL, Zhang Q, Sodek J. Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-I, osteopontin). Nucleic Acids Res\u20081989;17:10119.","DOI":"10.1093\/nar\/17.23.10119"},{"key":"2022061002321380800_BIB63","doi-asserted-by":"crossref","unstructured":"Tezuka K, Sato T, Kamioka H, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun\u20081992;186:911\u20137.","DOI":"10.1016\/0006-291X(92)90832-6"},{"key":"2022061002321380800_BIB64","doi-asserted-by":"crossref","unstructured":"Kerr JM, Fisher LW, Termine JD, Young MF. The cDNA cloning and RNA distribution of bovine osteopontin. Gene\u20081991;108:237\u201343.","DOI":"10.1016\/0378-1119(91)90439-I"},{"key":"2022061002321380800_BIB65","doi-asserted-by":"crossref","unstructured":"Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin\u2014a molecule for all seasons. Q J Med\u20082002;95:3\u201313.","DOI":"10.1093\/qjmed\/95.1.3"},{"key":"2022061002321380800_BIB66","doi-asserted-by":"crossref","unstructured":"Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J\u20082005;390:285\u201392.","DOI":"10.1042\/BJ20050341"},{"key":"2022061002321380800_BIB67","doi-asserted-by":"crossref","unstructured":"Sorensen ES, Hojrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci\u20081995;4:2040\u20139.","DOI":"10.1002\/pro.5560041009"},{"key":"2022061002321380800_BIB68","doi-asserted-by":"crossref","unstructured":"Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun\u20082001;280:460\u20135.","DOI":"10.1006\/bbrc.2000.4146"},{"key":"2022061002321380800_BIB69","doi-asserted-by":"crossref","unstructured":"Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J\u20081994;300:723\u20138.","DOI":"10.1042\/bj3000723"},{"key":"2022061002321380800_BIB70","doi-asserted-by":"crossref","unstructured":"Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodelling. J Cell Biochem Suppl\u20081998;30\u20131:92\u2013102.","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<92::AID-JCB13>3.0.CO;2-A"},{"key":"2022061002321380800_BIB71","doi-asserted-by":"crossref","unstructured":"Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics\u20081990;7:491\u2013502.","DOI":"10.1016\/0888-7543(90)90191-V"},{"key":"2022061002321380800_BIB72","doi-asserted-by":"crossref","unstructured":"Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J\u20081993;7:1475\u201382.","DOI":"10.1096\/fasebj.7.15.8262332"},{"key":"2022061002321380800_BIB73","doi-asserted-by":"crossref","unstructured":"Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J\u20081994;303:255\u201362.","DOI":"10.1042\/bj3030255"},{"key":"2022061002321380800_BIB74","doi-asserted-by":"crossref","unstructured":"Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a ras-activated enhancer in the mouse OPN promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol\u20081995;15:476\u201387.","DOI":"10.1128\/MCB.15.1.476"},{"key":"2022061002321380800_BIB75","unstructured":"Chang PL, Prince CW. 1\u03b1,25-Dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6. Cancer Res\u20081991;51:2144\u201350."},{"key":"2022061002321380800_BIB76","doi-asserted-by":"crossref","unstructured":"Tezuka K, Denhardt DT, Rodan GA, Harada S. Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J Biol Chem\u20081996;271:22713\u20137.","DOI":"10.1074\/jbc.271.37.22713"},{"key":"2022061002321380800_BIB77","doi-asserted-by":"crossref","unstructured":"Safran JB, Butler WT, Farach-Carson MC. Modulation of osteopontin post-translational state by 1,25-(OH)2-vitamin D3. Dependence on Ca2+ influx. J Biol Chem\u20081998;273:29935\u201341.","DOI":"10.1074\/jbc.273.45.29935"},{"key":"2022061002321380800_BIB78","doi-asserted-by":"crossref","unstructured":"Weber GF, Cantor H. The immunology of Eta-1\/osteopontin. Cytokine Growth Factor Rev\u20081996;7:241\u20138.","DOI":"10.1016\/S1359-6101(96)00030-5"},{"key":"2022061002321380800_BIB79","doi-asserted-by":"crossref","unstructured":"Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest\u20082001;107:1055\u201361.","DOI":"10.1172\/JCI12980"},{"key":"2022061002321380800_BIB80","doi-asserted-by":"crossref","unstructured":"Newham P, Humphries MJ. Integrin adhesion receptors: structure, function and implications for biomedicine. Mol Med Today\u20081996;2:304\u201313.","DOI":"10.1016\/1357-4310(96)10021-6"},{"key":"2022061002321380800_BIB81","doi-asserted-by":"crossref","unstructured":"Hu DD, Hoyer JR, Smith JW. Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin \u03b1v\u03b23. J Biol Chem\u20081995;270:9917\u201325.","DOI":"10.1074\/jbc.270.17.9917"},{"key":"2022061002321380800_BIB82","doi-asserted-by":"crossref","unstructured":"Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D. Engagement of the osteoclast integrin \u03b1v\u03b23 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology\u20081995;136:2984\u201392.","DOI":"10.1210\/endo.136.7.7540546"},{"key":"2022061002321380800_BIB83","doi-asserted-by":"crossref","unstructured":"Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the \u03b14\u03b21 integrin. J Cell Sci\u20081998;111:1165\u201374.","DOI":"10.1242\/jcs.111.9.1165"},{"key":"2022061002321380800_BIB84","doi-asserted-by":"crossref","unstructured":"Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by \u03b19\u03b21 integrin. J Biol Chem\u20081996;271:28485\u201391.","DOI":"10.1074\/jbc.271.45.28485"},{"key":"2022061002321380800_BIB85","doi-asserted-by":"crossref","unstructured":"Denda S, Reichardt LF, Muller U. Identification of osteopontin as a novel ligand for the integrin \u03b18\u03b21 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell\u20081998;9:1425\u201335.","DOI":"10.1091\/mbc.9.6.1425"},{"key":"2022061002321380800_BIB86","doi-asserted-by":"crossref","unstructured":"Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and \u03b23 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res\u20081995;77:665\u201372.","DOI":"10.1161\/01.RES.77.4.665"},{"key":"2022061002321380800_BIB87","doi-asserted-by":"crossref","unstructured":"Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta\u20081996;1314:13\u201324.","DOI":"10.1016\/S0167-4889(96)00067-5"},{"key":"2022061002321380800_BIB88","doi-asserted-by":"crossref","unstructured":"Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Osteopontin at the tumor\/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci\u20081995;760:83\u2013100.","DOI":"10.1111\/j.1749-6632.1995.tb44622.x"},{"key":"2022061002321380800_BIB89","doi-asserted-by":"crossref","unstructured":"Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta\u20081989;996:43\u20138.","DOI":"10.1016\/0167-4838(89)90092-7"},{"key":"2022061002321380800_BIB90","doi-asserted-by":"crossref","unstructured":"Bayless KJ, Davis GE. Identification of dual \u03b14\u03b21 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol Chem\u20082001;276:13483\u20139.","DOI":"10.1074\/jbc.M011392200"},{"key":"2022061002321380800_BIB91","doi-asserted-by":"crossref","unstructured":"Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem\u20082001;276:28261\u20137.","DOI":"10.1074\/jbc.M103608200"},{"key":"2022061002321380800_BIB92","doi-asserted-by":"crossref","unstructured":"Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell\u20081994;5:565\u201374.","DOI":"10.1091\/mbc.5.5.565"},{"key":"2022061002321380800_BIB93","doi-asserted-by":"crossref","unstructured":"Yokasaki Y, Sheppard D. Mapping of the cryptic integrin-binding site in osteopontin suggests a new mechanism by which thrombin can regulate inflammation and tissue repair. Trends Cardiovasc Med\u20082000;10:155\u20139.","DOI":"10.1016\/S1050-1738(00)00055-4"},{"key":"2022061002321380800_BIB94","doi-asserted-by":"crossref","unstructured":"Ponta H, Wainwright D, Herrlich P. The CD44 protein family. Int J Biochem Cell Biol\u20081998;30:299\u2013305.","DOI":"10.1016\/S1357-2725(97)00152-0"},{"key":"2022061002321380800_BIB95","doi-asserted-by":"crossref","unstructured":"Herrera-Gayol A, Jothy S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol\u20081999;66:149\u201356.","DOI":"10.1006\/exmp.1999.2251"},{"key":"2022061002321380800_BIB96","doi-asserted-by":"crossref","unstructured":"Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. J Clin Pathol\u20081999;52:189\u201396.","DOI":"10.1136\/mp.52.4.189"},{"key":"2022061002321380800_BIB97","doi-asserted-by":"crossref","unstructured":"Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science\u20081996;271:509\u201312.","DOI":"10.1126\/science.271.5248.509"},{"key":"2022061002321380800_BIB98","unstructured":"Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate \u03b21-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid thereby stimulating cell motility and chemotaxis. Cancer Res\u20081999;59:219\u201326."},{"key":"2022061002321380800_BIB99","doi-asserted-by":"crossref","unstructured":"Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis\u20082005;22:663\u201373.","DOI":"10.1007\/s10585-006-9007-0"},{"key":"2022061002321380800_BIB100","doi-asserted-by":"crossref","unstructured":"Weber GF, Ashkar S, Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians\u20081997;109:1\u20139.","DOI":"10.1126\/science.271.5248.509"},{"key":"2022061002321380800_BIB101","doi-asserted-by":"crossref","unstructured":"Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell\u20081979;16:885\u201393.","DOI":"10.1016\/0092-8674(79)90103-X"},{"key":"2022061002321380800_BIB102","doi-asserted-by":"crossref","unstructured":"Senger DR, Wirth DF, Hynes RO. Transformation-specific secreted phosphoproteins. Nature\u20081980;268:619\u201321.","DOI":"10.1038\/286619a0"},{"key":"2022061002321380800_BIB103","doi-asserted-by":"crossref","unstructured":"Prince CW. Secondary structure predictions for rat osteopontin. Connect Tissue Res\u20081989;21:15\u201320.","DOI":"10.3109\/03008208909049991"},{"key":"2022061002321380800_BIB104","doi-asserted-by":"crossref","unstructured":"Smith JH, Denhardt DT. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. J Cell Biochem\u20081987;34:13\u201322.","DOI":"10.1002\/jcb.240340103"},{"key":"2022061002321380800_BIB105","doi-asserted-by":"crossref","unstructured":"Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar\/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun\u20081988;157:166\u201373.","DOI":"10.1016\/S0006-291X(88)80028-7"},{"key":"2022061002321380800_BIB106","unstructured":"Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res\u20081992;12:43\u20137."},{"key":"2022061002321380800_BIB107","unstructured":"Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncog\u20081993;4:95\u2013114."},{"key":"2022061002321380800_BIB108","doi-asserted-by":"crossref","unstructured":"Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer\u20081990;46:133\u20137.","DOI":"10.1002\/ijc.2910460124"},{"key":"2022061002321380800_BIB109","doi-asserted-by":"crossref","unstructured":"Uede T, Katagiri Y, Iizuka J, Murakami M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol Immunol\u20081997;41:641\u20138.","DOI":"10.1111\/j.1348-0421.1997.tb01906.x"},{"key":"2022061002321380800_BIB110","doi-asserted-by":"crossref","unstructured":"Ramos KS. Redox regulation of c-Ha-ras and osteopontin signalling in vascular smoth muscle cells: implications in chemical atherogenesis. Annu Rev Pharmacol Toxicol\u20081999;39:243\u201365.","DOI":"10.1146\/annurev.pharmtox.39.1.243"},{"key":"2022061002321380800_BIB111","doi-asserted-by":"crossref","unstructured":"Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med\u20081999;222:124\u201338.","DOI":"10.1046\/j.1525-1373.1999.d01-122.x"},{"key":"2022061002321380800_BIB112","doi-asserted-by":"crossref","unstructured":"Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol\u20081996;8:724\u201330.","DOI":"10.1016\/S0955-0674(96)80115-3"},{"key":"2022061002321380800_BIB113","doi-asserted-by":"crossref","unstructured":"Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci\u20081998;54:541\u20138.","DOI":"10.1007\/s000180050182"},{"key":"2022061002321380800_BIB114","doi-asserted-by":"crossref","unstructured":"Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol\u20082000;190:310\u201329.","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P"},{"key":"2022061002321380800_BIB115","doi-asserted-by":"crossref","unstructured":"Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev\u20081999;18:359\u201375.","DOI":"10.1023\/A:1006317125454"},{"key":"2022061002321380800_BIB116","unstructured":"Wong NC, Mueller BM, Barbas CF, et al. \u03b1v Integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis\u20081998;16:50\u201361."},{"key":"2022061002321380800_BIB117","doi-asserted-by":"crossref","unstructured":"Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem\u20082000;78:465\u201375.","DOI":"10.1002\/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C"},{"key":"2022061002321380800_BIB118","doi-asserted-by":"crossref","unstructured":"Ellison JA, Velier JJ, Spera P, et al. Osteopontin and its integrin receptor \u03b1v\u03b23 are upregulated during formation of the glial scar after focal stroke. Stroke\u20081998;29:1698\u2013706.","DOI":"10.1161\/01.STR.29.8.1698"},{"key":"2022061002321380800_BIB119","doi-asserted-by":"crossref","unstructured":"Carey I, Williams CL, Ways DK, Noti JD. Overexpression of protein kinase C-\u03b1 in MCF-7 breast cancer cells results in differential regulation and expression of \u03b1v\u03b23 and \u03b1v\u03b25. Int J Oncol\u20081999;15:127\u201336.","DOI":"10.3892\/ijo.15.1.127"},{"key":"2022061002321380800_BIB120","doi-asserted-by":"crossref","unstructured":"Noti JD. Adherence to osteopontin via \u03b1v\u03b23 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-\u03b1. Int J Oncol\u20082000;17:1237\u201343.","DOI":"10.3892\/ijo.17.6.1237"},{"key":"2022061002321380800_BIB121","doi-asserted-by":"crossref","unstructured":"Zohar R, Suzuki N, Suzuki K, et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol\u20082000;184:118\u201330.","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y"},{"key":"2022061002321380800_BIB122","unstructured":"Fujisaki T, Tanaka Y, Fujii K, et al. CD44 Stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res\u20081999;59:4427\u201334."},{"key":"2022061002321380800_BIB123","doi-asserted-by":"crossref","unstructured":"Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst\u20082002;94:513\u201321.","DOI":"10.1093\/jnci\/94.7.513"},{"key":"2022061002321380800_BIB124","unstructured":"Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res\u20081985;45:5818\u201323."},{"key":"2022061002321380800_BIB125","unstructured":"Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res\u20082002;62:3417\u201327."},{"key":"2022061002321380800_BIB126","unstructured":"Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene\u20081996;13:97\u2013104."},{"key":"2022061002321380800_BIB127","unstructured":"Su L, Mukherjee AB, Mukherjee BB. Expression of antisense osteopontin mRNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene\u20081995;10:2163\u20139."},{"key":"2022061002321380800_BIB128","unstructured":"Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res\u20081994;54:832\u20137."},{"key":"2022061002321380800_BIB129","doi-asserted-by":"crossref","unstructured":"Sato M, Morii E, Komori T, et al. Transcriptional regulation of osteopontin gene in vivo by PEBP2\u03b1A\/CBFA1 and ETS1 in the skeletal tissues. Oncogene\u20081998;17:1517\u201325.","DOI":"10.1038\/sj.onc.1202064"},{"key":"2022061002321380800_BIB130","doi-asserted-by":"crossref","unstructured":"Noda M, Vogel RL, Craig AM, et al. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (Spp-1 or osteopontin) gene expression. Proc Natl Acad Sci U S A\u20081990;87:9995\u20139.","DOI":"10.1073\/pnas.87.24.9995"},{"key":"2022061002321380800_BIB131","doi-asserted-by":"crossref","unstructured":"Bidder M, Shao JS, Charlton-Kachigian N, et al. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem\u20082002;277:44485\u201396.","DOI":"10.1074\/jbc.M206235200"},{"key":"2022061002321380800_BIB132","doi-asserted-by":"crossref","unstructured":"El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with \u03b2-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem\u20082004;279:20794\u2013806.","DOI":"10.1074\/jbc.M311131200"},{"key":"2022061002321380800_BIB133","doi-asserted-by":"crossref","unstructured":"Webb CP, Taylor GA, Jeffers M, et al. Evidence for a role of Met-HGF\/SF during Ras-mediated tumorigenesis\/metastasis. Oncogene\u20081998;17:2019\u201325.","DOI":"10.1038\/sj.onc.1202135"},{"key":"2022061002321380800_BIB134","doi-asserted-by":"crossref","unstructured":"Trusolino L, Cavassa S, Angelini P, et al. HGF\/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J\u20082000;14:1629\u201340.","DOI":"10.1096\/fj.99-0844com"},{"key":"2022061002321380800_BIB135","doi-asserted-by":"crossref","unstructured":"Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer\u20081997;72:1\u201322.","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z"},{"key":"2022061002321380800_BIB136","doi-asserted-by":"crossref","unstructured":"Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst\u20081997;89:1260\u201370.","DOI":"10.1093\/jnci\/89.17.1260"},{"key":"2022061002321380800_BIB137","doi-asserted-by":"crossref","unstructured":"DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer\u20082000;36:1258\u201368.","DOI":"10.1016\/S0959-8049(00)00094-0"},{"key":"2022061002321380800_BIB138","doi-asserted-by":"crossref","unstructured":"Nguyen DH, Catling AD, Webb DJ, et al. Myosin light chain kinase functions downstream of RAS\/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol\u20081999;146:149\u201364.","DOI":"10.1083\/jcb.146.999.149"},{"key":"2022061002321380800_BIB139","doi-asserted-by":"crossref","unstructured":"Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene\u20081999;18:4237\u201346.","DOI":"10.1038\/sj.onc.1202799"},{"key":"2022061002321380800_BIB140","doi-asserted-by":"crossref","unstructured":"Yebra M, Parry GC, Stromblad S, et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin \u03b1v\u03b25-directed cell migration. J Biol Chem\u20081996;271:29393\u20139.","DOI":"10.1074\/jbc.271.46.29393"},{"key":"2022061002321380800_BIB141","unstructured":"Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with \u03b1v\u03b25 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res\u20081999;59:5307\u201314."},{"key":"2022061002321380800_BIB142","doi-asserted-by":"crossref","unstructured":"Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signalling. J Cell Biol\u20081999;147:89\u2013104.","DOI":"10.1083\/jcb.147.1.89"},{"key":"2022061002321380800_BIB143","doi-asserted-by":"crossref","unstructured":"Teti A, Farina AR, Villanova I, et al. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer\u20081998;77:82\u201393.","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<82::AID-IJC14>3.0.CO;2-B"},{"key":"2022061002321380800_BIB144","doi-asserted-by":"crossref","unstructured":"Bendeck MP, Irvin C, Reidy M, et al. Smooth muscle cell matrix metalloproteinase production is stimulated via \u03b1v\u03b23 integrin. Arterioscler Thromb Vasc Biol\u20082000;20:1467\u201372.","DOI":"10.1161\/01.ATV.20.6.1467"},{"key":"2022061002321380800_BIB145","doi-asserted-by":"crossref","unstructured":"Costa C, Soares R, Schmitt F. Angiogenesis: now and then. Acta Pathol Microbiol Immunol Scand\u20082004;112:402\u201312.","DOI":"10.1111\/j.1600-0463.2004.apm11207-0802.x"},{"key":"2022061002321380800_BIB146","doi-asserted-by":"crossref","unstructured":"Soares R, Reis-Filho J, Gartner F, Schmitt F. VEGF, TGF\u03b1 and estrogen receptors: possible crosstalks and interactions. Am J Pathol\u20082002;160:381\u20132.","DOI":"10.1016\/S0002-9440(10)64381-7"},{"key":"2022061002321380800_BIB147","doi-asserted-by":"crossref","unstructured":"Soares R, Guo S, Russo J, Schmitt F. Role of the estrogen antagonist ICI 182,780 in vessel assembly and apoptosis of endothelial cells. Ultrastruct Pathol\u20082003;27:33\u20139.","DOI":"10.1080\/01913120309946"},{"key":"2022061002321380800_BIB148","doi-asserted-by":"crossref","unstructured":"Soares R, Balogh G, Guo S, Gartner F, Russo J, Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol\u20082004;18:2333\u201343.","DOI":"10.1210\/me.2003-0362"},{"key":"2022061002321380800_BIB149","doi-asserted-by":"crossref","unstructured":"Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin \u03b1v\u03b23 for angiogenesis. Science\u20081994;264:569\u201371.","DOI":"10.1126\/science.7512751"},{"key":"2022061002321380800_BIB150","doi-asserted-by":"crossref","unstructured":"Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin \u03b1v\u03b23 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell\u20081994;79:1157\u201364.","DOI":"10.1016\/0092-8674(94)90007-8"},{"key":"2022061002321380800_BIB151","doi-asserted-by":"crossref","unstructured":"Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-\u03baB mediates \u03b1v\u03b23 integrin-induced endothelial cell survival. J Cell Biol\u20081998;141:1083\u201393.","DOI":"10.1083\/jcb.141.4.1083"},{"key":"2022061002321380800_BIB152","doi-asserted-by":"crossref","unstructured":"Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an \u03b1v\u03b23-induced, NF-\u03baB-dependent survival factor for endothelial cells. J Biol Chem\u20082000;275:20959\u201362.","DOI":"10.1074\/jbc.C000290200"},{"key":"2022061002321380800_BIB153","unstructured":"Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor\/vascular endothelial growth factor through cooperative mechanisms involving the \u03b1v\u03b23 integrin, osteopontin, and thrombin. Am J Pathol\u20081996;149:293\u2013305."},{"key":"2022061002321380800_BIB154","unstructured":"Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, \u03b1v\u03b23 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer\u20082000;82:1967\u201373."},{"key":"2022061002321380800_BIB155","doi-asserted-by":"crossref","unstructured":"Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med\u20081999;160:1269\u201373.","DOI":"10.1164\/ajrccm.160.4.9807094"},{"key":"2022061002321380800_BIB156","doi-asserted-by":"crossref","unstructured":"Denhardt DT, Chambers AF. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem\u20081994;56:48\u201351.","DOI":"10.1002\/jcb.240560109"},{"key":"2022061002321380800_BIB157","doi-asserted-by":"crossref","unstructured":"Rollo EE, Denhardt DT. Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology\u20081996;88:642\u20137.","DOI":"10.1046\/j.1365-2567.1996.d01-691.x"},{"key":"2022061002321380800_BIB158","doi-asserted-by":"crossref","unstructured":"Feng B, Rollo EE, Denhardt DT. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis\u20081995;13:453\u201362.","DOI":"10.1007\/BF00118184"},{"key":"2022061002321380800_BIB159","doi-asserted-by":"crossref","unstructured":"Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem\u20081994;269:711\u20135.","DOI":"10.1016\/S0021-9258(17)42407-0"},{"key":"2022061002321380800_BIB160","doi-asserted-by":"crossref","unstructured":"Rollo EE, Laskin DL, Denhardt DT. Osteopontin inhibits nitric oxide production and cytotoxycity by activated RA W264.7 macrophages. J Leukoc Biol\u20081996;60:397\u2013404.","DOI":"10.1002\/jlb.60.3.397"},{"key":"2022061002321380800_BIB161","doi-asserted-by":"crossref","unstructured":"Scott JA, Weir ML, Wilson SM, Xuan JW, Chambers AF, McCormack DG. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol\u20081998;275:H2258\u201365.","DOI":"10.1152\/ajpheart.1998.275.6.H2258"},{"key":"2022061002321380800_BIB162","doi-asserted-by":"crossref","unstructured":"Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev\u20081998;17:107\u201318.","DOI":"10.1023\/A:1005912906436"},{"key":"2022061002321380800_BIB163","doi-asserted-by":"crossref","unstructured":"Brennan PA. The actions and interactions of nitric oxide in solid tumours. Eur J Surg Oncol\u20082000;26:434\u20137.","DOI":"10.1053\/ejso.1999.0917"},{"key":"2022061002321380800_BIB164","doi-asserted-by":"crossref","unstructured":"Kolb JP. Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. Leukemia\u20082000;14:1685\u201394.","DOI":"10.1038\/sj.leu.2401896"},{"key":"2022061002321380800_BIB165","doi-asserted-by":"crossref","unstructured":"Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer\u20081996;15:311\u201323.","DOI":"10.1016\/0169-5002(95)00595-1"},{"key":"2022061002321380800_BIB166","doi-asserted-by":"crossref","unstructured":"Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer\u20081998;79:502\u20138.","DOI":"10.1002\/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3"},{"key":"2022061002321380800_BIB167","doi-asserted-by":"crossref","unstructured":"Casson AG, Wilson SM, McCart JA, et al. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer\u20081997;72:739\u201345.","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T"},{"key":"2022061002321380800_BIB168","doi-asserted-by":"crossref","unstructured":"Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer\u20081998;79:127\u201332.","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V"},{"key":"2022061002321380800_BIB169","unstructured":"Thalman GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res\u20081999;5:2271\u20137."},{"key":"2022061002321380800_BIB170","unstructured":"Saitoh Y, Kuratsu JI, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest\u20081995;72:53\u20135."},{"key":"2022061002321380800_BIB171","unstructured":"Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis\u20081997;17:1\u201315."},{"key":"2022061002321380800_BIB172","unstructured":"Hirota S, Ito A, Nagoshi J, et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest\u20081995;72:64\u20139."},{"key":"2022061002321380800_BIB173","unstructured":"Bellahcene A, Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer\u20081997;84:17\u201324."},{"key":"2022061002321380800_BIB174","doi-asserted-by":"crossref","unstructured":"Maki M, Hirota S, Kaneko Y, Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int\u20082000;50:531\u20135.","DOI":"10.1046\/j.1440-1827.2000.01075.x"},{"key":"2022061002321380800_BIB175","doi-asserted-by":"crossref","unstructured":"Hirota S, Nakajima Y, Yoshimine T, et al. Expression of bone-related protein messenger RNA in human meningiomas: possible involvement of osteopontin in development of psammoma bodies. J Neuropathol Exp Neurol\u20081995;54:698\u2013703.","DOI":"10.1097\/00005072-199509000-00012"},{"key":"2022061002321380800_BIB176","unstructured":"Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med\u20081998;122:1087\u201390."},{"key":"2022061002321380800_BIB177","unstructured":"Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med\u20081997;121:578\u201384."},{"key":"2022061002321380800_BIB178","doi-asserted-by":"crossref","unstructured":"Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K, Kohri K. Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int\u20081999;62:155\u20138.","DOI":"10.1159\/000030381"},{"key":"2022061002321380800_BIB179","doi-asserted-by":"crossref","unstructured":"Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol\u20081998;29:1250\u20134.","DOI":"10.1016\/S0046-8177(98)90253-2"},{"key":"2022061002321380800_BIB180","doi-asserted-by":"crossref","unstructured":"Liapis H, Adler LM, Wick MR, Rader JS. Expression of \u03b1v\u03b23 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol\u20081997;28:443\u20139.","DOI":"10.1016\/S0046-8177(97)90033-2"},{"key":"2022061002321380800_BIB181","unstructured":"Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol\u20081994;145:610\u201323."},{"key":"2022061002321380800_BIB182","doi-asserted-by":"crossref","unstructured":"Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem\u20081996;29:231\u20139.","DOI":"10.1016\/0009-9120(96)84728-A"},{"key":"2022061002321380800_BIB183","unstructured":"Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res\u20081997;3:605\u201311."},{"key":"2022061002321380800_BIB184","doi-asserted-by":"crossref","unstructured":"Vanacker JM, Pattersson K, Gustafsson JA, Laudet V. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) \u03b1, but not by (ER) \u03b2. EMBO J\u20081999;18:4270\u20139.","DOI":"10.1093\/emboj\/18.15.4270"},{"key":"2022061002321380800_BIB185","doi-asserted-by":"crossref","unstructured":"Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer\u20082003;3:243\u201352.","DOI":"10.1038\/nrc1041"},{"key":"2022061002321380800_BIB186","doi-asserted-by":"crossref","unstructured":"Hayes DF. Serum (circulating) tumour markers for breast cancer. Recent Results Cancer Res\u20081996;140:101\u201313.","DOI":"10.1007\/978-3-642-79278-6_12"},{"key":"2022061002321380800_BIB187","doi-asserted-by":"crossref","unstructured":"O'Brien N, Maguire TM, O'Donovan N, et al. Mammaglobin: a promising marker for breast cancer. Clin Chem\u20082002;48:1362\u20134.","DOI":"10.1093\/clinchem\/48.8.1362"},{"key":"2022061002321380800_BIB188","doi-asserted-by":"crossref","unstructured":"Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer\u20082002;3:281\u20137.","DOI":"10.3816\/CBC.2002.n.032"},{"key":"2022061002321380800_BIB189","doi-asserted-by":"crossref","unstructured":"Corradini P, Voena C, Astolfi M, et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol\u20082001;12:1693\u20138.","DOI":"10.1023\/A:1013573108945"},{"key":"2022061002321380800_BIB190","doi-asserted-by":"crossref","unstructured":"Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat\u20082001;66:159\u201364.","DOI":"10.1023\/A:1010692132669"},{"key":"2022061002321380800_BIB191","doi-asserted-by":"crossref","unstructured":"Sanchez R, Nguyen D, Rocha W, White JH, Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioassays\u20082002;24:244\u201354.","DOI":"10.1002\/bies.10066"},{"key":"2022061002321380800_BIB192","unstructured":"Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alfa and estrogen-related receptor gama associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res\u20082002;62:6510\u20138."},{"key":"2022061002321380800_BIB193","unstructured":"MacGrogan G, Jollet I, Huet S, et al. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol\u20081997;10:769\u201376."},{"key":"2022061002321380800_BIB194","doi-asserted-by":"crossref","unstructured":"Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer\u20082001;93:162\u201371.","DOI":"10.1002\/ijc.1312"},{"key":"2022061002321380800_BIB195","doi-asserted-by":"crossref","unstructured":"Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol\u20081998;16:462\u20139.","DOI":"10.1200\/JCO.1998.16.2.462"},{"key":"2022061002321380800_BIB196","doi-asserted-by":"crossref","unstructured":"Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch\u20082002;440:16\u201321.","DOI":"10.1007\/s004280100487"},{"key":"2022061002321380800_BIB197","doi-asserted-by":"crossref","unstructured":"Paredes J, Stove C, Stove V, et al. P-Cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res\u20082004;64:8309\u201317.","DOI":"10.1158\/0008-5472.CAN-04-0795"},{"key":"2022061002321380800_BIB198","doi-asserted-by":"crossref","unstructured":"Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch\u20082005;447:688\u201394.","DOI":"10.1007\/s00428-005-0010-7"},{"key":"2022061002321380800_BIB199","doi-asserted-by":"crossref","unstructured":"Brakora KA, Lee H, Yusuf R, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol\u20082004;93:361\u20135.","DOI":"10.1016\/j.ygyno.2004.01.050"},{"key":"2022061002321380800_BIB200","doi-asserted-by":"crossref","unstructured":"Fisher LW, Jain A, Tayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res\u20082004;10:8501\u201311.","DOI":"10.1158\/1078-0432.CCR-04-1072"},{"key":"2022061002321380800_BIB201","doi-asserted-by":"crossref","unstructured":"Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med\u20081999;10:79\u201398.","DOI":"10.1177\/10454411990100010401"},{"key":"2022061002321380800_BIB202","doi-asserted-by":"crossref","unstructured":"Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin mediated via distinct cell surface integrins. Role of \u03b1v\u03b23 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest\u20081995;95:713\u201324.","DOI":"10.1172\/JCI117718"},{"key":"2022061002321380800_BIB203","doi-asserted-by":"crossref","unstructured":"Barry ST, Ludbrook SB, Murrison E, Horgan CM. A regulated interaction between \u03b15\u03b21 integrin and osteopontin. Biochem Biophys Res Commun\u20082000;267:764\u20139.","DOI":"10.1006\/bbrc.1999.2032"},{"key":"2022061002321380800_BIB204","doi-asserted-by":"crossref","unstructured":"Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the \u03b14\u03b21 integrin-osteopontin interaction. Exp Cell Res\u20082000;258:342\u201351.","DOI":"10.1006\/excr.2000.4941"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/16\/6\/1087\/2245379\/1087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/16\/6\/1087\/2245379\/1087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:12:54Z","timestamp":1654866774000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/16\/6\/1087\/260292\/The-Role-of-Osteopontin-in-Tumor-Progression-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":204,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,4]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-06-1008","relation":{},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}